Taro Pharmaceutical Indus
(NYSE:TARO)
$42.29
0.03[0.07%]
At close: Mar 28
$42.29
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$43.00
Lowest Price Target1
$43.00
Consensus Price Target1
$43.00

Taro Pharmaceutical Indus Stock (NYSE:TARO), Analyst Ratings, Price Targets, Predictions

Taro Pharmaceutical Industries Ltd has a consensus price target of $43, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on January 18, 2024, January 25, 2023, and August 15, 2022. With an average price target of $44 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 4.04% upside for Taro Pharmaceutical Industries Ltd from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Jan
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Taro Pharmaceutical Indus

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
01/18/2024TAROBuy Now
Taro Pharmaceutical Indus
$42.291.68%HC Wainwright & Co.
Raghuram Selvaraju
$43 → $43DowngradeBuy → NeutralGet Alert
01/25/2023TAROBuy Now
Taro Pharmaceutical Indus
$42.29-17.24%HC Wainwright & Co.
Raghuram Selvaraju
$54 → $35MaintainsBuyGet Alert
08/15/2022TAROBuy Now
Taro Pharmaceutical Indus
$42.2927.69%HC Wainwright & Co.
Raghuram Selvaraju
$73 → $54MaintainsBuyGet Alert
01/31/2022TAROBuy Now
Taro Pharmaceutical Indus
$42.2972.62%HC Wainwright & Co.
Raghuram Selvaraju
$75 → $73MaintainsBuyGet Alert
01/18/2022TAROBuy Now
Taro Pharmaceutical Indus
$42.2977.35%HC Wainwright & Co.
Raghuram Selvaraju
$82 → $75MaintainsBuyGet Alert
07/28/2021TAROBuy Now
Taro Pharmaceutical Indus
$42.2993.9%HC Wainwright & Co.
Raghuram Selvaraju
MaintainsBuyGet Alert
06/02/2021TAROBuy Now
Taro Pharmaceutical Indus
$42.2989.17%HC Wainwright & Co.
Raghuram Selvaraju
MaintainsBuyGet Alert

FAQ

Q

What is the target price for Taro Pharmaceutical Indus (TARO)?

A

The latest price target for Taro Pharmaceutical Indus (NYSE: TARO) was reported by HC Wainwright & Co. on January 18, 2024. The analyst firm set a price target for $43.00 expecting TARO to rise to within 12 months (a possible 1.68% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Taro Pharmaceutical Indus (TARO)?

A

The latest analyst rating for Taro Pharmaceutical Indus (NYSE: TARO) was provided by HC Wainwright & Co., and Taro Pharmaceutical Indus downgraded their neutral rating.

Q

When was the last upgrade for Taro Pharmaceutical Indus (TARO)?

A

There is no last upgrade for Taro Pharmaceutical Indus.

Q

When was the last downgrade for Taro Pharmaceutical Indus (TARO)?

A

The last downgrade for Taro Pharmaceutical Industries Ltd happened on January 18, 2024 when HC Wainwright & Co. changed their price target from $43 to $43 for Taro Pharmaceutical Industries Ltd.

Q

When is the next analyst rating going to be posted or updated for Taro Pharmaceutical Indus (TARO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taro Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taro Pharmaceutical Indus was filed on January 18, 2024 so you should expect the next rating to be made available sometime around January 18, 2025.

Q

Is the Analyst Rating Taro Pharmaceutical Indus (TARO) correct?

A

While ratings are subjective and will change, the latest Taro Pharmaceutical Indus (TARO) rating was a downgraded with a price target of $43.00 to $43.00. The current price Taro Pharmaceutical Indus (TARO) is trading at is $42.29, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.